Skip to main content

6 Result(s)

within J. P. Droz Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Chapter

    Effects of Treatment of Malignant Lymphomas on the Granulocytic Progenitor Cells (CFUc)

    Study of the after-effects of therapy on the healthy organs is one of the main preoccupations of oncology. Although progress in therapeutics has clearly improved the prognosis for malignant lymphomas, the afte...

    C. Parmentier, D. Maraninchi, N. Morardet, J. P. Droz… in Lymphoid Neoplasias II (1978)

  2. No Access

    Article

    Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

     Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...

    C. Maulard, J. P. Droz, D. Jessueld, M. Housset… in Cancer Chemotherapy and Pharmacology (1995)

  3. No Access

    Article

    Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

    Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...

    C. Maulard, P. Richaud, J. P. Droz, D. Jessueld… in Cancer Chemotherapy and Pharmacology (1995)

  4. Article

    Open Access

    Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

    Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progressi...

    G Freyer, P Rougier, R Bugat, J-P Droz, M Marty, H Bleiberg… in British Journal of Cancer (2000)

    Download PDF (237 KB)

  5. Article

    Open Access

    A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

    This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colo...

    T Bachelot, F Gomez, P Biron, I Ray-Coquard, P Soler-Michel… in British Journal of Cancer (2002)

    Download PDF (200 KB) View Article

  6. Article

    Open Access

    The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area

    The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched contr...

    A-C Piketty, A Fléchon, A Laplanche, E Nouyrigat, J-P Droz… in British Journal of Cancer (2005)

    Download PDF (115 KB) View Article